MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Core Insights - A study published in the Journal of Atherosclerosis and Thrombosis indicates that tipelukast (MN-001) and its metabolite MN-002 positively influence cholesterol metabolism in patients [1][2] Company Overview - MediciNova, Inc. is a biopharmaceutical company listed on NASDAQ (MNOV) and the Tokyo Stock Exchange (Code Number: 4875) [1] - The company is focused on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases, with a pipeline that includes 11 clinical programs [5] Research Findings - The study titled "Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast" shows that MN-002 significantly enhances cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1 [2] - These findings suggest a new mechanism of action for potential therapeutic strategies against atherosclerosis and other metabolic disorders [2][3] Clinical Development - Previous clinical studies indicated that MN-001 improved serum lipid profiles in patients with Non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, especially in those with type 2 diabetes [4] - MediciNova is conducting a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, Type 2 diabetes, and NAFLD, with enrollment nearing completion [4]